LakeShore Biopharma Co's Days Sales Outstanding for the
six
months ended in Mar. 2025 was 391.78.
LakeShore Biopharma Co's Days Inventory for the
six
months ended in Mar. 2025 was 912.76.
LakeShore Biopharma Co's Days Payable for the
six
months ended in Mar. 2025 was 206.63.
Therefore, LakeShore Biopharma Co's Cash Conversion Cycle (CCC) for the
six
months ended in Mar. 2025 was 1,097.91.
LakeShore Biopharma Co (OTCPK:LSBCF) Cash Conversion Cycle Explanation
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
LakeShore Biopharma Co Cash Conversion Cycle Related Terms
LakeShore Biopharma Co Cash Conversion Cycle Historical Data
* Premium members only.
The historical data trend for LakeShore Biopharma Co's Cash Conversion Cycle can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LakeShore Biopharma Co Cash Conversion Cycle Chart
LSBCF vs ACUT, PPCB, ENSC: Cash Conversion Cycle Comparison
For the Biotechnology subindustry, LakeShore Biopharma Co's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
LakeShore Biopharma Co Cash Conversion Cycle vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, LakeShore Biopharma Co's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where LakeShore Biopharma Co's Cash Conversion Cycle falls into.
LakeShore Biopharma Co Cash Conversion Cycle Calculation
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
LakeShore Biopharma Co's Cash Conversion Cycle for the fiscal year that ended in Mar. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Cash Conversion Cycle of 1,097.91 mean?
LakeShore Biopharma Co (LSBCF) has a Cash Conversion Cycle of 1,097.91 as of Mar. 2025. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on LakeShore Biopharma Co and its competitors.
Is LakeShore Biopharma Co's Cash Conversion Cycle too high?
LakeShore Biopharma Co's current Cash Conversion Cycle is 1,097.91. The Biotechnology industry median Cash Conversion Cycle is 102.38. LakeShore Biopharma Co's value of 1,097.91 is 972.4% above this industry median.
How does LakeShore Biopharma Co's Cash Conversion Cycle compare to ACUT and PPCB?
LakeShore Biopharma Co's Cash Conversion Cycle of 1,097.91 can be compared against companies in the Biotechnology industry. The industry median Cash Conversion Cycle is 102.38. LakeShore Biopharma Co's value of 1,097.91 is 972.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Biotechnology company?
The median Cash Conversion Cycle among Biotechnology companies is 102.38, based on 875 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. LakeShore Biopharma Co's current Cash Conversion Cycle of 1,097.91 is 972.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on LakeShore Biopharma Co and its competitors. For the Biotechnology industry, the median Cash Conversion Cycle is 102.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. LakeShore Biopharma Co's current Cash Conversion Cycle is 1,097.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LakeShore Biopharma Co stock overvalued right now?
LakeShore Biopharma Co (LSBCF) has a current Cash Conversion Cycle of 1,097.91. The current Cash Conversion Cycle is 1,097.91 and 972.4% above the Biotechnology industry median of 102.38. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For LakeShore Biopharma Co (LSBCF), the current Cash Conversion Cycle is 1,097.91 as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
LakeShore Biopharma Co Ltd is a biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA immunomodulating technology platform and a new generation of preventive and therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B, Influenza, Shingles, and other virus infections. The company operates in China, the United States, Singapore, and the Philippines.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSBCF has been successfully added to your 